Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 721 to 735 of 1835 results for carers

  1. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  3. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  4. Lumasiran for treating primary hyperoxaluria type 1 (HST25)

    Evidence-based recommendations on lumasiran (Oxlumo) for primary hyperoxaluria type 1 in people of all ages.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST25

  5. Transition between inpatient mental health settings and community or care home settings (QS159)

    This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 September 2017
    View quality statements

    Sections for QS159

  6. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527)

    Evidence-based recommendations on beta interferons (Avonex, Betaferon, Extavia, Rebif) and glatiramer acetate (Copaxone) for treating multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    27 June 2018
    View recommendations

    Sections for TA527

  7. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    In development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548]

    Awaiting development Reference number: GID-TA11723 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Decitabine–cedazuridine with venetoclax for treating acute myeloid leukaemia when intensive induction chemotherapy is unsuitable [ID6601]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 11 February 2026.

    Technology appraisal guidance
    In consultation

  11. Baxdrostat for treating uncontrolled or resistant hypertension [ID6623]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 9 February 2026.

    Technology appraisal guidance
    In consultation

  12. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 12 February 2026.

    Technology appraisal guidance
    In consultation

  13. Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over ID6542

    In development Reference number: GID-TA11525 Expected publication date:  10 February 2027

    Technology appraisal guidance
    In development

  14. Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672]

    Awaiting development Reference number: GID-TA11878 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463]

    In development Reference number: GID-TA11590 Expected publication date: TBC

    Technology appraisal guidance
    In development